04 September 2019
Visiongain has launched a new pharma report Actinic Keratosis Treatment Market Forecast 2019-2029: By Therapy (Topical, Surgery, Photodynamic Therapy), By Drug Class, By End Use, By Region, And Segment Forecasts
The global Actinic Keratosis Treatment market is poised for rapid growth between 2019 and 2029. The market is driven by the high prevalence of the disease, rapid technological advances and increased consumer awareness.
Topical therapies will generate the highest revenue among other therapeutic segments during the forecast period. However, photodynamic therapy is expected to witness healthy growth during the forecast period. The increasing trend of photodynamic and combination therapies should favorably promote growth in the near future.
Leading companies featured in the report include Bausch Health Companies Inc.; LEO Pharma A/S; Almirall, S.A.; Biofrontera, Inc.; Nestlé S.A.; Sun Pharmaceutical Industries Ltd.; Novartis International AG; 3M Pharmaceuticals Inc.; Hill Dermaceuticals, Inc.; and Mylan N.V.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 207 336 6100.
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
Diagnostic imaging technology such as MRI and CT scans has become more precise and accessible, due to which radiology has increasingly become a key foundation of modern medicine.
20 September 2019
Although price is still the most important competitive advantage for a biosimilar company, current discount rates are not enough to automatically convince the key stakeholders of a biosimilar’s value.
10 September 2019
The global anti-infective agents market is one that is driven by innovation. This is vital for maintaining the rich pipeline of anti-infective agents seen in the market today.
09 September 2019
Thyroid disease is one of today’s most prevalent hormonal illnesses. Hyperthyroidism, hypothyroidism, and thyroid nodules are the most common thyroid gland disorders.